These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 11367126)
1. Update on tenofovir (PMPA) compassionate access study. AIDS Treat News; 1999 Nov; (No 331):4. PubMed ID: 11367126 [TBL] [Abstract][Full Text] [Related]
2. Tenofovir (PMPA) compassionate access study opens. AIDS Treat News; 1999 Nov; (No 330):1. PubMed ID: 11367168 [TBL] [Abstract][Full Text] [Related]
3. Upcoming compassionate use programs for two new antiretrovirals will begin this fall. Schouten J STEP Perspect; 1999; 99(3):16. PubMed ID: 11366864 [TBL] [Abstract][Full Text] [Related]
5. [Tenofovir in Study 903. Also effective and tolerable in first-line therapy]. MMW Fortschr Med; 2002 Aug; 144(33-34):61. PubMed ID: 12380158 [No Abstract] [Full Text] [Related]
6. [Further indications for tenofovir]. Dtsch Med Wochenschr; 2003 Sep; 128(39):2037. PubMed ID: 14565207 [No Abstract] [Full Text] [Related]
7. [Tenofovir--a new option for combination therapy]. Polk B Med Monatsschr Pharm; 2002 Apr; 25(4):140-1. PubMed ID: 12017127 [No Abstract] [Full Text] [Related]
8. [No comparison with NRTI. Tenofovir is robust against resistance trouble]. MMW Fortschr Med; 2002 Apr; 144 Suppl 1():65. PubMed ID: 12043079 [No Abstract] [Full Text] [Related]
9. Tenofovir: Gilead applies for approval; expanded access liberalized. Gilden D AIDS Treat News; 2001 May; (364):2-3, 1. PubMed ID: 11569959 [TBL] [Abstract][Full Text] [Related]
10. [96-week treatment outcome confirms long term efficacy of tenofovir DF]. Dtsch Med Wochenschr; 2003 May; 128(19):1074-5. PubMed ID: 12774796 [No Abstract] [Full Text] [Related]
11. Effect of tenofovir on didanosine absorption in patients with HIV. Pecora Fulco P; Kirian MA Ann Pharmacother; 2003 Sep; 37(9):1325-8. PubMed ID: 12921517 [TBL] [Abstract][Full Text] [Related]
13. Marked elevation of the creatine phosphokinase level in a patient receiving tenofovir. Shere-Wolfe KD; Verley JR Clin Infect Dis; 2002 Nov; 35(9):1137. PubMed ID: 12384851 [No Abstract] [Full Text] [Related]
14. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. Miller MD; Margot N; Lu B; Zhong L; Chen SS; Cheng A; Wulfsohn M J Infect Dis; 2004 Mar; 189(5):837-46. PubMed ID: 14976601 [TBL] [Abstract][Full Text] [Related]
15. [First nucleotide analog against HIV. Lowers viral load also in drug resistance]. MMW Fortschr Med; 2002 Aug; 144(33-34):60-1. PubMed ID: 12380157 [No Abstract] [Full Text] [Related]
16. The potential place of tenofovir in antiretroviral treatment regimens. Gazzard BG Int J Clin Pract; 2001 Dec; 55(10):704-9. PubMed ID: 11777298 [TBL] [Abstract][Full Text] [Related]